PncA gene mutations associated with pyrazinamide resistance in drug-resistant Tuberculosis, South Africa and Georgia

Salim Allana, Elena Shashkina, Barun Mathema, Nino Bablishvili, Nestani Tukvadze, N. Sarita Shah, Russell R. Kempker, Henry M. Blumberg, Pravi Moodley, Koleka Mlisana, James C.M. Brust, Neel R. Gandhi

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polymorphisms in the pncA gene for 70% of multidrug-resistant and 96% of extensively drugresistant Mycobacterium tuberculosis isolates from South Africa and Georgia. Assessment of pyrazinamide susceptibility may be prudent before using it in regimens for drugresistant tuberculosis.

Original languageEnglish (US)
Pages (from-to)491-495
Number of pages5
JournalEmerging infectious diseases
Volume23
Issue number3
DOIs
StatePublished - Mar 2017

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'PncA gene mutations associated with pyrazinamide resistance in drug-resistant Tuberculosis, South Africa and Georgia'. Together they form a unique fingerprint.

  • Cite this

    Allana, S., Shashkina, E., Mathema, B., Bablishvili, N., Tukvadze, N., Shah, N. S., Kempker, R. R., Blumberg, H. M., Moodley, P., Mlisana, K., Brust, J. C. M., & Gandhi, N. R. (2017). PncA gene mutations associated with pyrazinamide resistance in drug-resistant Tuberculosis, South Africa and Georgia. Emerging infectious diseases, 23(3), 491-495. https://doi.org/10.3201/eid2303.161034